Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
复制标题
原发性免疫缺陷患者接种BNT 162 b2 mRNA COVID-19疫苗后的体液和细胞反应。
DOI：
10.3389/fimmu.2021.727850
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Palma P
中科院分区：
文献类型：
--
作者：
Amodio D;Ruggiero A;Sgrulletti M;Pighi C;Cotugno N;Medri C;Morrocchi E;Colagrossi L;Russo C;Zaffina S;Di Matteo G;Cifaldi C;Di Cesare S;Rivalta B;Pacillo L;Santilli V;Giancotta C;Manno EC;Ciofi Degli Atti M;Raponi M;Rossi P;Finocchi A;Cancrini C;Perno CF;Moschese V;Palma P
大规模的SARS-CoV-2疫苗接种运动是战胜我们面临的全球大流行的唯一战略。免疫功能低下的患者是易患严重新冠肺炎的高危人群，因此在疫苗接种计划和疫苗效力研究中应优先考虑。然而，现有疫苗的有效性和安全性的大部分数据来自对健康个体进行的试验；因此，迫切需要对SARS-CoV2疫苗在这些人群中的免疫原性进行研究。在这里，我们进行了一项观察性纵向研究，与健康对照组(HC)相比，分析了BNT162b2mRNA新冠肺炎疫苗接种后的体液和细胞反应。我们发现，IEI组和HC组在第二次预定剂量后一周的抗SARS-CoV-2抗体显著增加，并且HC和IEI组的抗原特异性CD4+CD40L+T细胞总体上有统计学上的显著扩张。5名IEI患者没有出现任何特异性的CD4+CD40L+T细胞反应，其中一名患者也不能产生任何体液反应。这些数据引起了人们对使用抗体反应作为接种SARS-CoV-2疫苗后保护性免疫的唯一衡量标准的免疫学关注。综上所述，这些发现表明，对这一亚群的疫苗诱导免疫的评估还应包括对抗原特异性T细胞的量化。
Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global pandemic we are facing. Immunocompromised patients represent a vulnerable population at high risk of developing severe COVID-19 and thus should be prioritized in the vaccination programs and in the study of the vaccine efficacy. Nevertheless, most data on efficacy and safety of the available vaccines derive from trials conducted on healthy individuals; hence, studies on immunogenicity of SARS-CoV2 vaccines in such populations are deeply needed. Here, we perform an observational longitudinal study analyzing the humoral and cellular response following the BNT162b2 mRNA COVID-19 vaccine in a cohort of patients affected by inborn errors of immunity (IEI) compared to healthy controls (HC). We show that both IEI and HC groups experienced a significant increase in anti-SARS-CoV-2 Abs 1 week after the second scheduled dose as well as an overall statistically significant expansion of the Ag-specific CD4+CD40L+ T cells in both HC and IEI. Five IEI patients did not develop any specific CD4+CD40L+ T cellular response, with one of these patients unable to also mount any humoral response. These data raise immunologic concerns about using Ab response as a sole metric of protective immunity following vaccination for SARS-CoV-2. Taken together, these findings suggest that evaluation of vaccine-induced immunity in this subpopulation should also include quantification of Ag-specific T cells.
登录
查看更多内容
影响因子：
82.9
作者：
Levine-Tiefenbrun, Matan;Yelin, Idan;Kishony, Roy
通讯作者：
Kishony, Roy
影响因子：
13.6
作者：
Moser, B. A.;Steinhardt, R. C.;Esser-Kahn, A. P.
通讯作者：
Esser-Kahn, A. P.
影响因子：
3.4
作者：
Piatosa, Barbara;Wolska-Kusnierz, Beata;Bernatowska, Ewa
通讯作者：
Bernatowska, Ewa
影响因子：
3.2
作者：
Duchamp, Marie;Sterlin, Delphine;Diabate, Aminata;Uring-Lambert, Beatrice;Guerin-El Khourouj, Valerie;Le Mauff, Brigitte;Monnier, Delphine;Malcus, Christophe;Labalette, Myriam;Picard, Capucine
通讯作者：
Picard, Capucine
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group